<DOC>
	<DOCNO>NCT02701374</DOCNO>
	<brief_summary>In Post-Herpetic Neuralgia ( PHN ) patient : - To conduct explorative investigation efficacy safety repeat oral dos TRK-700 via randomize double blind comparative study - To measure plasma concentration TRK-700 metabolite</brief_summary>
	<brief_title>Efficacy Safety TRK-700 Patient With Post-Herpetic Neuralgia</brief_title>
	<detailed_description />
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Neuralgia , Postherpetic</mesh_term>
	<criteria>Patients pain persist least 3 month onset herpes zoster Patients whose average pain score Numerical Rating Scale ( NRS ) past 24 hour preliminary enrollment least 4 Patients another skin disease may affect evaluation pain site PHN Patients pain PHN may affect evaluation pain Patients pain suspect mainly psychogenic Patients receive neurolytic neurosurgical therapy PHN</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>84 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>TRK-700</keyword>
	<keyword>Post-Herpetic Neuralgia</keyword>
</DOC>